Prof Sacks, USA reviews the available data about PPAR alpha delta and the Elafibranor clinical program (RESOVE-IT). The interim results were presented earlier this year. They are somewhat disappointing (especially regarding the primary liver outcome).

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In

five × 3 =